ENTRY       D03106                      Drug
NAME        Bexarotene (JAN/USAN/INN);
            Targretin (TN)
PRODUCT     TARGRETIN (Bausch Health US)
            TARGRETIN (Bausch Health US)
  GENERIC   BEXAROTENE (ANI Pharmaceuticals)
            BEXAROTENE (Actavis Pharma)
            BEXAROTENE (Amneal Pharmaceuticals NY LLC)
            BEXAROTENE (Amneal Pharmaceuticals NY LLC)
            BEXAROTENE (AvKARE)
            BEXAROTENE (Hikma Pharmaceuticals USA)
            BEXAROTENE (Mylan Pharmaceuticals)
            BEXAROTENE (Oceanside Pharmaceuticals)
            BEXAROTENE (Oceanside Pharmaceuticals)
            BEXAROTENE (Upsher-Smith Laboratories)
FORMULA     C24H28O2
EXACT_MASS  348.2089
MOL_WEIGHT  348.4779
CLASS       Vitamin and mineral
             DG01604  Retinol derivative
            Metabolizing enzyme inducer
             DG02853  CYP3A/CYP3A4 inducer
REMARK      Therapeutic category: 4291
            ATC code: L01XF03
            Product: D03106<JP/US>
EFFICACY    Antineoplastic
  DISEASE   Cutaneous T-cell lymphoma [DS:H01463]
TARGET      NR2B (RXR) [HSA:6256 6257 6258] [KO:K08524 K08525 K08526]
  PATHWAY   hsa03320(6256+6257+6258)  PPAR signaling pathway
            hsa04920(6256+6257+6258)  Adipocytokine signaling pathway
            hsa05200(6256+6257+6258)  Pathways in cancer
INTERACTION CYP induction: CYP3A [HSA:1576 1577 1551]
STR_MAP     map07223  Retinoic acid receptor (RAR) and retinoid X receptor (RXR) agonists/antagonists
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XF Retinoids for cancer treatment
                 L01XF03 Bexarotene
                  D03106  Bexarotene (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Retinoids
               Bexarotene
                D03106  Bexarotene (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D03106  Bexarotene (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Vitamin and mineral
              DG01604  Retinol derivative
               D03106  Bexarotene
             Metabolizing enzyme inducer
              DG02853  CYP3A/CYP3A4 inducer
               D03106  Bexarotene
            Target-based classification of drugs [BR:br08310]
             Nuclear receptors
              Hepatocyte nuclear factor 4 like receptors
               Retinoid X receptor (RXR)
                NR2B (RXR)
                 D03106  Bexarotene (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03106
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03106
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03106
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03106
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D03106
DBLINKS     CAS: 153559-49-0
            PubChem: 17397261
            ChEBI: 50859
            PDB-CCD: 9RA
            LigandBox: D03106
            NIKKAJI: J612.549B
ATOM        26
            1   C8y C    14.9800  -16.8700
            2   C8y C    14.9800  -15.4700
            3   C1z C    13.7900  -14.7700
            4   C1x C    12.6000  -15.4700
            5   C1x C    12.6000  -16.8700
            6   C1z C    13.7900  -17.5700
            7   C8x C    16.2400  -17.5700
            8   C8y C    17.4300  -16.8700
            9   C8y C    17.4300  -15.4700
            10  C8x C    16.2400  -14.7700
            11  C2c C    18.6200  -17.5700
            12  C8y C    19.8800  -16.8700
            13  C1a C    12.8100  -18.5500
            14  C1a C    14.7700  -18.5500
            15  C1a C    14.8400  -13.7900
            16  C1a C    12.8100  -13.7900
            17  C2a C    18.6200  -18.9700
            18  C1a C    18.6200  -14.7700
            19  C8x C    21.0700  -17.5700
            20  C8x C    22.2600  -16.8700
            21  C8y C    22.2600  -15.4700
            22  C8x C    21.0700  -14.7700
            23  C8x C    19.8800  -15.4700
            24  C6a C    23.4500  -14.7700
            25  O6a O    24.7100  -15.5400
            26  O6a O    23.4500  -13.4400
BOND        28
            1    11  12 1
            2     1   7 1
            3     7   8 2
            4     8   9 1
            5     9  10 2
            6    10   2 1
            7     5   6 1
            8     6   1 1
            9     1   2 2
            10    6  13 1
            11    2   3 1
            12    6  14 1
            13    3   4 1
            14    3  15 1
            15    4   5 1
            16    3  16 1
            17    8  11 1
            18   11  17 2
            19    9  18 1
            20   12  19 2
            21   19  20 1
            22   20  21 2
            23   21  22 1
            24   22  23 2
            25   12  23 1
            26   21  24 1
            27   24  25 1
            28   24  26 2
///
